Impact of recipient CMV serostatus on outcome after HSCT: recent studies
Reference, by first author . | No. patients . | Underlying disease . | T-cell-depleted donors, % . | Unrelated donors, % . | Results among CMV-seropositive recipients compared with CMV-seronegative recipients with a seronegative donor . |
|---|---|---|---|---|---|
| Broers7 * | 115 | Mixed | 95 | 0 | 24% absolute decline in OS (P = .01) |
| McGlave8 | 1423 | CML | 23 | 100 | 20% relative decline in DFS (P = .002) |
| Cornelissen9 * | 127 | ALL | 26 | 100 | 38% relative decline in DFS (P = .05) |
| Craddock6 † | 106 | CML | 100 | 100 | 22% absolute decline in OS (P = .006) |
| Kroger10 | 125 | Mixed | 100 | 100 | 41% absolute decline in OS (P < .001) |
| Castro-Malaspina11 | 510 | MDS | 24 | 100 | 46% relative decline in DFS (P = .001) |
| Nichols4 | 1750 | Mixed | 0 | 57 | 26% relative decline in OS (P = .03) |
| Kollman3 | 6978 | Mixed | 25 | 100 | 7% absolute decline in OS (P < .001) |
| Meijer12 | 48 | Mixed | 100 | 100 | 41% absolute rise in TRM (P < .001) |
| Doney13 | 182 | ALL | 0 | 52 | 99% relative rise in TRM (P = .01) |
Reference, by first author . | No. patients . | Underlying disease . | T-cell-depleted donors, % . | Unrelated donors, % . | Results among CMV-seropositive recipients compared with CMV-seronegative recipients with a seronegative donor . |
|---|---|---|---|---|---|
| Broers7 * | 115 | Mixed | 95 | 0 | 24% absolute decline in OS (P = .01) |
| McGlave8 | 1423 | CML | 23 | 100 | 20% relative decline in DFS (P = .002) |
| Cornelissen9 * | 127 | ALL | 26 | 100 | 38% relative decline in DFS (P = .05) |
| Craddock6 † | 106 | CML | 100 | 100 | 22% absolute decline in OS (P = .006) |
| Kroger10 | 125 | Mixed | 100 | 100 | 41% absolute decline in OS (P < .001) |
| Castro-Malaspina11 | 510 | MDS | 24 | 100 | 46% relative decline in DFS (P = .001) |
| Nichols4 | 1750 | Mixed | 0 | 57 | 26% relative decline in OS (P = .03) |
| Kollman3 | 6978 | Mixed | 25 | 100 | 7% absolute decline in OS (P < .001) |
| Meijer12 | 48 | Mixed | 100 | 100 | 41% absolute rise in TRM (P < .001) |
| Doney13 | 182 | ALL | 0 | 52 | 99% relative rise in TRM (P = .01) |
CML indicates chronic myelogenous leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; OS, overall survival; DFS, disease-free survival; TRM, transplant-related mortality.
The seropositive group includes some seronegative recipients with a seropositive donor.
The difference in OS is between seropositive recipients and seronegative recipients (some of whom have seropositive donors); the difference between seropositive recipients and D—/R— patients is 14% at 5 years.